Search

everythinglearnresearchcommunity

for

Search:↓

The new Brigatinib nanocarrier is more effective against lung cancer cells than the free drug.

Drugs targeting the Androgen Receptor are effective for treating prostate cancer and other androgen-related conditions.

The oral contraceptive alone is the preferred treatment for hirsutism, as adding the GnRH analog showed no significant benefit.

TRASER effectively targets blood vessels and hair follicles for potential use in vascular and hair removal treatments.

TICE salvage chemotherapy is effective for treating germ-cell tumors with poor prognosis.

Erlotinib can cause unusual hair growth, like long eyelashes and facial hair.

Biomedical imaging has greatly improved understanding and treatment of solid tumors.

A new topical treatment for hair loss shows promise by targeting androgen receptors.

The treatment helped a transgender woman stop drinking, improved her mental health, and reduced her gender dysphoria.

Carboplatin-paclitaxel is preferred for advanced lung cancer due to its balance of affordability and patient well-being.

Localized heat or specific injections can prevent chemotherapy-induced hair loss without affecting cancer treatment.

Abnormal Hedgehog signaling in blood cancers may help tumors grow and resist chemotherapy, suggesting potential for targeted treatments.

The combination therapy significantly improved Riehl’s melanosis in patients without serious side effects.

Dihydrotestosterone increases growth and spread of human brain cancer cells, and blocking its formation might help treat this cancer.

Some drugs linked to growth hormones may increase the chance of hair loss in women.

In 2007, prostate cancer research improved understanding of risk, diagnosis, and treatment, but also showed heart risks with certain therapies and the need for personalized care.

Adjusting estradiol-ANGPT2 levels can promote hair growth in female pattern hair loss.

Erlotinib can cause significant but temporary hair loss in lung cancer patients.

Targeting ornithine decarboxylase can help prevent skin cancer.

Dermatologists are crucial for managing skin side effects in metastatic melanoma patients using vemurafenib and ipilimumab.

Ion channels play a key role in ovarian cancer growth and treatment resistance.

Cyproterone acetate is a safe treatment that causes modest feminization in transgender female adolescents, and works better with added estrogens.

Immunomodulatory therapies are effective for treating cutaneous lymphoma, particularly in early stages.

Hormone treatments can help with women's skin and hair disorders, but they need careful monitoring and more research.

The conclusion is that removing both ovaries is the best treatment for excess male hormones in postmenopausal women, with medication as another option, and managing insulin resistance is important for diagnosis and treatment.

The conclusion is that the best initial treatment for hirsutism is usually oral contraceptives, with the addition of antiandrogens or insulin sensitizers if needed, and topical eflornithine or laser treatments as supplementary options.

Skin side effects from cancer drugs targeting EGFR can affect treatment adherence but can be managed with antibiotics like tetracycline.

Identical p53 gene mutations in different cancers suggest the need for careful treatment.

Most patients experienced mild to moderate skin problems during a trial for a desmoid tumor treatment.

Modifying steroidal inhibitors shows promise for developing new cancer treatments.